205 related articles for article (PubMed ID: 12610158)
1. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.
Suphaphiphat P; Thitithanyanont A; Paca-Uccaralertkun S; Essex M; Lee TH
J Virol; 2003 Mar; 77(6):3832-7. PubMed ID: 12610158
[TBL] [Abstract][Full Text] [Related]
2. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
Cormier EG; Dragic T
J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor.
Suphaphiphat P; Essex M; Lee TH
Virology; 2007 Mar; 360(1):182-90. PubMed ID: 17101166
[TBL] [Abstract][Full Text] [Related]
4. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
5. CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.
Wang WK; Dudek T; Zhao YJ; Brumblay HG; Essex M; Lee TH
Proc Natl Acad Sci U S A; 1998 May; 95(10):5740-5. PubMed ID: 9576954
[TBL] [Abstract][Full Text] [Related]
6. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
7. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
8. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
[TBL] [Abstract][Full Text] [Related]
9. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
10. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.
Li Y; Rey-Cuille MA; Hu SL
AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1473-9. PubMed ID: 11709091
[TBL] [Abstract][Full Text] [Related]
11. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
Platt EJ; Kuhmann SE; Rose PP; Kabat D
J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
[TBL] [Abstract][Full Text] [Related]
12. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.
de Parseval A; Bobardt MD; Chatterji A; Chatterji U; Elder JH; David G; Zolla-Pazner S; Farzan M; Lee TH; Gallay PA
J Biol Chem; 2005 Nov; 280(47):39493-504. PubMed ID: 16157597
[TBL] [Abstract][Full Text] [Related]
13. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
Maeda Y; Foda M; Matsushita S; Harada S
J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
[TBL] [Abstract][Full Text] [Related]
14. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
15. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.
Sato H; Kato K; Takebe Y
Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559
[TBL] [Abstract][Full Text] [Related]
16. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
[TBL] [Abstract][Full Text] [Related]
17. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
Platt EJ; Shea DM; Rose PP; Kabat D
J Virol; 2005 Apr; 79(7):4357-68. PubMed ID: 15767436
[TBL] [Abstract][Full Text] [Related]
18. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
19. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications.
Wang WK; Dudek T; Essex M; Lee TH
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4558-62. PubMed ID: 10200301
[TBL] [Abstract][Full Text] [Related]
20. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
Gorry PR; Dunfee RL; Mefford ME; Kunstman K; Morgan T; Moore JP; Mascola JR; Agopian K; Holm GH; Mehle A; Taylor J; Farzan M; Wang H; Ellery P; Willey SJ; Clapham PR; Wolinsky SM; Crowe SM; Gabuzda D
Virology; 2007 May; 362(1):163-78. PubMed ID: 17239419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
